Skip to main content

Table 2 Summary of Genz-644282 and The-0504 efficacy in tumor-bearing mice models of human cell lines of different origin

From: High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors

Tumor model

TGI (%)

RESPONSE at 1.9 mg/Kg

ORR (%)

Genz-644282

The-0504

Genz-644282a

The-0504

Pancreatic (PaCa44)

64.2

100

33.3% SD

100% MCR

16.7

100

66.7% PD

Colorectal (HT29)

Not available

Not available

33.3% SD

66.7% CR

16.6

100

66.7% PD

33.3% PR

Breast (MDA-MB 231)

70.1

100

16.7% SD

83.3% MCR

0

100

83.3% PD

16.7% CR

Liver (HepG2)

55.5

100

25.0% PR

100% MCR

25.0

100

75.0% PD

Pancreatic (PDX)a

0

93.6

100% PD

33.3% MCR

0

83.3

16.7% CR,

33.3% PR,

16.7% SD

  1. a Nab-paclitaxel at 10 mg/Kg instead of Genz-644282 was used in PDX model
  2. TGI Tumor Growth Inhibition, ORR Objective Response Rate, MCR Maintained Complete Response, CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive Disease